Ultragenyx (RARE) news
Recent news
Morgan Stanley raises target price to $74 from $67 for Ultragenyx Pharmaceutical Inc.
Morgan Stanley has raised its price target for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) to $74 from $67, while maintaining its Overweight rating . This adjustment follows recent developments in the company’s clinical pipeline and financial strategy. On November 5, 2025, the firm had previously…
AInvest Wire · Aug 21, 2026Ultragenyx Pharmaceutical shares up 5.5% after securing FDA nod for rare metabolic disorder gene therapy
AInvest Wire · Aug 20, 2026Ultragenyx's Genglycose gets FDA accelerated approval
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced on August 19, 2026, that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Genglycose (DTX401), an AAV8 gene therapy for the treatment of Glycogen Storage Disease Type Ia (GSDIa). The FDA accepted the Biologics…
AInvest Wire · Aug 19, 2026Ultragenyx Pharmaceutical: will grant Esjay a non-exclusive, royalty-free license to market its generic version of Dojolvi beginning January 1, 2033
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced that it will grant Esjay a non-exclusive, royalty-free license to market a generic version of Dojolvi (triheptanoin) beginning January 1, 2033. Dojolvi is currently approved by the U.S. Food and Drug Administration (FDA), Health Canada,…
AInvest Wire · Aug 11, 2026UltraGenyx Pharmaceutical - Co and Bri settle DOJOLVI patent litigation with Esjay Pharma - SEC filing
AInvest Wire · Aug 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.